We therefore aimed to study the association between genetic alterations of ARID1A and the PI3K/AKT pathway in CCA and investigate the effect of AKT inhibitor on ARID1A-deficient CCA cell lines. This evidence concerns the gene PIK3CA and cholangiocarcinoma.